AVIEW NeuroCAD Adds 20,000 Cases in Cumulative Usage Over Six Months

Coreline Soft announced on April 7 that its brain imaging diagnostic assistance AI solution, AVIEW NeuroCAD, has surpassed a cumulative usage of 50,000 cases. This marks an increase of 20,000 cases in about six months, following the 30,000 cases recorded in October of last year.

Coreline Soft's emergency AI solution 'AIVIEW NeuroCAD' operation screen. Coreline Soft

Coreline Soft's emergency AI solution 'AIVIEW NeuroCAD' operation screen. Coreline Soft

View original image

The company explained that the solution is primarily being utilized in the non-reimbursed and selective reimbursement markets, and its usage frequency within medical institutions is increasing.


As of the first half of this year, which marks the second year since NeuroCAD's launch, the solution accounted for more than 10% of Coreline Soft's domestic sales. The company analyzed that usage has grown as non-reimbursed prescriptions have expanded following its designation as an innovative medical device.


There have also been examples of its use in emergency medical settings. Coreline Soft stated that in regional hub hospitals, the AI analysis results are provided to medical staff immediately after CT scans, helping to reduce preparation time for treatment.



Coreline Soft plans to expand the application of AVIEW NeuroCAD to cover aortic dissection and pulmonary embolism in the future. In addition, the company is pursuing a shift from its existing one-time license-based business model to a subscription-based (SaaS) revenue structure.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing